首页 > 最新文献

Head and Neck-Journal for the Sciences and Specialties of the Head and Neck最新文献

英文 中文
Risk Factors Influencing Medication-Related Osteonecrosis of the Jaws (MRONJ) Following Dental Extraction Among Osteoporotic Patients in Taiwan. 影响台湾骨质疏松患者拔牙后药物相关性颌骨坏死的危险因素。
IF 2.3 3区 医学 Q1 OTORHINOLARYNGOLOGY Pub Date : 2024-11-29 DOI: 10.1002/hed.28011
Ling-Ying Wei, Yi-Wen Cheng, Wei-Yih Chiu, Sang-Heng Kok, Hao-Hong Chang, Shih-Jung Cheng, Jang-Jaer Lee

Aim: Antiresorptive therapy (ART) is commonly used in osteoporotic patients to prevent bone loss. This retrospective cohort study aimed to identify the risk factors associated with medication-related osteonecrosis of the jaw (MRONJ) in osteoporotic patients receiving dental extraction during ART.

Materials and methods: Data were collected from 937 patients with 1067 dental extractions conducted between January 2003 and May 2022, including 519 patients on oral alendronate, 276 on denosumab, and 172 on zoledronate. Multivariate logistic regression analysis was employed to assess potential risk factors.

Results: Regression model analysis revealed older age (AOR 1.09 per year; 95% CI, 1.06-1.12) and drug treatment exceeding 24 months (AOR 2.07; 95% CI, 1.29-3.30) as significant risk factors. A drug interruption of 3 or more months prior to tooth extraction lowered MRONJ risk (AOR 0.11; 95% CI, 0.07-0.17). Stratified by drug type, denosumab users had significantly lower risk of MRONJ after extraction (AOR 0.14; 95% CI, 0.07-0.27) compared to those on other medications. Factors of drug duration ≥ 24 months, < 3 months of interruption, and posterior mandibular tooth extraction posed the highest synergistic MRONJ risk (AOR 80.29; 95% CI, 33.05-195.09).

Conclusion: Our results suggest an association between a three-month ART interruption prior to tooth extraction and reduced MRONJ risk, especially in long-term ART patients undergoing posterior mandibular extractions. However, these findings require validation through prospective randomized controlled trials.

Clinical relevance: Scientific Rationale for Study: The study fills crucial knowledge gaps regarding MRONJ risks in osteoporotic patients undergoing dental extraction during antiresorptive therapy (ART), providing a foundation for informed clinical decisions.

Principal findings: Noteworthy findings include elevated MRONJ risk with older age and prolonged ART, the protective effect of a 3-month ART interruption, and denosumab users showing significantly reduced postextraction MRONJ risk.

Practical implications: Implementing a 3-month ART interruption before dental extraction is recommended to reduce MRONJ occurrences.

目的:抗骨吸收治疗(ART)是预防骨质疏松症患者骨质流失的常用方法。本回顾性队列研究旨在确定在ART期间接受拔牙的骨质疏松症患者药物相关性颌骨骨坏死(MRONJ)的相关危险因素。材料与方法:收集2003年1月至2022年5月937例拔牙患者1067例的数据,其中口服阿仑膦酸盐519例,地诺单抗276例,唑来膦酸盐172例。采用多因素logistic回归分析评估潜在危险因素。结果:回归模型分析显示年龄较大(AOR为1.09 /年;95% CI, 1.06-1.12)和药物治疗超过24个月(AOR 2.07;95% CI, 1.29-3.30)为显著危险因素。拔牙前药物中断3个月或更长时间可降低MRONJ风险(AOR 0.11;95% ci, 0.07-0.17)。按药物类型分层,denosumab使用者提取后MRONJ的风险显著降低(AOR 0.14;95% CI, 0.07-0.27)。结论:我们的研究结果表明拔牙前三个月的ART中断与MRONJ风险降低有关,特别是在长期接受后下颌拔牙的ART患者中。然而,这些发现需要通过前瞻性随机对照试验来验证。临床相关性:研究的科学依据:该研究填补了关于骨质疏松症患者在接受抗吸收治疗(ART)期间拔牙时MRONJ风险的关键知识空白,为知情的临床决策提供了基础。主要发现:值得注意的发现包括随着年龄的增长和ART时间的延长,MRONJ风险升高,ART中断3个月的保护作用,denosumab使用者显示提取后MRONJ风险显着降低。实际意义:建议在拔牙前实施3个月的ART中断,以减少MRONJ的发生。
{"title":"Risk Factors Influencing Medication-Related Osteonecrosis of the Jaws (MRONJ) Following Dental Extraction Among Osteoporotic Patients in Taiwan.","authors":"Ling-Ying Wei, Yi-Wen Cheng, Wei-Yih Chiu, Sang-Heng Kok, Hao-Hong Chang, Shih-Jung Cheng, Jang-Jaer Lee","doi":"10.1002/hed.28011","DOIUrl":"https://doi.org/10.1002/hed.28011","url":null,"abstract":"<p><strong>Aim: </strong>Antiresorptive therapy (ART) is commonly used in osteoporotic patients to prevent bone loss. This retrospective cohort study aimed to identify the risk factors associated with medication-related osteonecrosis of the jaw (MRONJ) in osteoporotic patients receiving dental extraction during ART.</p><p><strong>Materials and methods: </strong>Data were collected from 937 patients with 1067 dental extractions conducted between January 2003 and May 2022, including 519 patients on oral alendronate, 276 on denosumab, and 172 on zoledronate. Multivariate logistic regression analysis was employed to assess potential risk factors.</p><p><strong>Results: </strong>Regression model analysis revealed older age (AOR 1.09 per year; 95% CI, 1.06-1.12) and drug treatment exceeding 24 months (AOR 2.07; 95% CI, 1.29-3.30) as significant risk factors. A drug interruption of 3 or more months prior to tooth extraction lowered MRONJ risk (AOR 0.11; 95% CI, 0.07-0.17). Stratified by drug type, denosumab users had significantly lower risk of MRONJ after extraction (AOR 0.14; 95% CI, 0.07-0.27) compared to those on other medications. Factors of drug duration ≥ 24 months, < 3 months of interruption, and posterior mandibular tooth extraction posed the highest synergistic MRONJ risk (AOR 80.29; 95% CI, 33.05-195.09).</p><p><strong>Conclusion: </strong>Our results suggest an association between a three-month ART interruption prior to tooth extraction and reduced MRONJ risk, especially in long-term ART patients undergoing posterior mandibular extractions. However, these findings require validation through prospective randomized controlled trials.</p><p><strong>Clinical relevance: </strong>Scientific Rationale for Study: The study fills crucial knowledge gaps regarding MRONJ risks in osteoporotic patients undergoing dental extraction during antiresorptive therapy (ART), providing a foundation for informed clinical decisions.</p><p><strong>Principal findings: </strong>Noteworthy findings include elevated MRONJ risk with older age and prolonged ART, the protective effect of a 3-month ART interruption, and denosumab users showing significantly reduced postextraction MRONJ risk.</p><p><strong>Practical implications: </strong>Implementing a 3-month ART interruption before dental extraction is recommended to reduce MRONJ occurrences.</p>","PeriodicalId":55072,"journal":{"name":"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142752142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Significance of REV7 Expression in p16-Negative Oropharyngeal Squamous Cell Carcinoma. P16阴性口咽鳞癌中REV7表达的意义
IF 2.3 3区 医学 Q1 OTORHINOLARYNGOLOGY Pub Date : 2024-11-28 DOI: 10.1002/hed.28015
Kaho Momiyama, Shohei Tsutsumi, Yasutaka Sakurai, Sachiyo Mogi, Shunsuke Miyamoto, Yoshiki Murakumo, Taku Yamashita

Background: REV7 is a multifunctional protein involved in various biological processes, including DNA damage response. REV7 expression in human cancer cells influences sensitivity to DNA-damaging agents, and its high expression level is reportedly associated with a poor prognosis in many carcinomas. However, the significance of REV7 expression in human papillomavirus 16-negative oropharyngeal squamous cell carcinoma (OPSCC) remains unclear.

Methods: REV7 expression was assessed by immunohistochemical analysis in 79 patients with HPV16-negative OPSCC. We evaluated the effects of inhibiting REV7 expression on the proliferation and cisplatin sensitivity of FaDu, an HPV16-negative pharyngeal SCC cell line.

Results: In patients with p16-negative OPSCC, the high-REV7-expression group experienced significantly shorter overall survival than the low-REV7-expression group (p = 0.03) in the Cox regression analysis. Furthermore, REV7-deficient FaDu cells showed suppressed cell growth and enhanced sensitivity to cisplatin in vitro.

Conclusions: REV7 expression is associated with a poor prognosis in HPV16-negative OPSCC.

背景:REV7是一种多功能蛋白,参与多种生物过程,包括DNA损伤反应。REV7在人类癌细胞中的表达影响着癌细胞对DNA损伤因子的敏感性,据报道,REV7的高表达水平与许多癌症的不良预后有关。然而,REV7在人乳头瘤病毒16阴性口咽鳞状细胞癌(OPSCC)中表达的意义仍不清楚:通过免疫组化分析评估了79例HPV16阴性口咽鳞癌患者的REV7表达情况。我们评估了抑制REV7表达对HPV16阴性咽部SCC细胞系FaDu的增殖和顺铂敏感性的影响:结果:在p16阴性OPSCC患者中,高REV7表达组的总生存期在Cox回归分析中明显短于低REV7表达组(P = 0.03)。此外,REV7缺陷的FaDu细胞在体外显示出细胞生长受抑制,对顺铂的敏感性增强:REV7的表达与HPV16阴性OPSCC的不良预后有关。
{"title":"Significance of REV7 Expression in p16-Negative Oropharyngeal Squamous Cell Carcinoma.","authors":"Kaho Momiyama, Shohei Tsutsumi, Yasutaka Sakurai, Sachiyo Mogi, Shunsuke Miyamoto, Yoshiki Murakumo, Taku Yamashita","doi":"10.1002/hed.28015","DOIUrl":"https://doi.org/10.1002/hed.28015","url":null,"abstract":"<p><strong>Background: </strong>REV7 is a multifunctional protein involved in various biological processes, including DNA damage response. REV7 expression in human cancer cells influences sensitivity to DNA-damaging agents, and its high expression level is reportedly associated with a poor prognosis in many carcinomas. However, the significance of REV7 expression in human papillomavirus 16-negative oropharyngeal squamous cell carcinoma (OPSCC) remains unclear.</p><p><strong>Methods: </strong>REV7 expression was assessed by immunohistochemical analysis in 79 patients with HPV16-negative OPSCC. We evaluated the effects of inhibiting REV7 expression on the proliferation and cisplatin sensitivity of FaDu, an HPV16-negative pharyngeal SCC cell line.</p><p><strong>Results: </strong>In patients with p16-negative OPSCC, the high-REV7-expression group experienced significantly shorter overall survival than the low-REV7-expression group (p = 0.03) in the Cox regression analysis. Furthermore, REV7-deficient FaDu cells showed suppressed cell growth and enhanced sensitivity to cisplatin in vitro.</p><p><strong>Conclusions: </strong>REV7 expression is associated with a poor prognosis in HPV16-negative OPSCC.</p>","PeriodicalId":55072,"journal":{"name":"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142741501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Beck Depression Inventory-II Response Following Parathyroidectomy for Primary Hyperparathyroidism: A Systematic Review and Meta-Analyses. 原发性甲状旁腺功能亢进症甲状旁腺切除术后的贝克抑郁量表-II 反应:系统回顾与元分析》。
IF 2.3 3区 医学 Q1 OTORHINOLARYNGOLOGY Pub Date : 2024-11-27 DOI: 10.1002/hed.28003
Om S Chitnis, Sabrina K Wagner, J Joseph Caraway, Nora L Watson, Rhonda J Allard, Michael I Orestes

Background: There is currently a lack of consensus regarding neuropsychiatric symptoms as an indication for parathyroidectomy in primary hyperparathyroidism (pHPT). The purpose of this study is to perform a systematic review and meta-analyses of pre- and postoperative Beck Depression Inventory-II (BDI-II) scores in patients with pHPT undergoing parathyroidectomy.

Methods: A search of the literature was performed using Embase, PubMed, Web of Science, PsycINFO, and OvidAll EBM Reviews. Studies were included if they evaluated BDI-II scores in pHPT patients before and after parathyroidectomy.

Results: The literature search returned 1554 studies, of which nine articles met criteria for inclusion. Baseline BDI-II scores were significantly higher in pHPT patients compared to control patients. pHPT patients experienced a statistically significant decrease in BDI-II scores at ≤ 1 and 6 months postoperatively.

Conclusions: Based on the results of this study, a BDI-II score ≥ 14 could potentially advocate for parathyroidectomy in patients with pHPT.

背景:关于神经精神症状作为原发性甲状旁腺功能亢进症(pHPT)甲状旁腺切除术的适应症,目前尚缺乏共识。本研究旨在对接受甲状旁腺切除术的pHPT患者术前和术后的贝克抑郁量表-II(BDI-II)评分进行系统回顾和荟萃分析:使用Embase、PubMed、Web of Science、PsycINFO和OvidAll EBM Reviews进行文献检索。对甲状旁腺切除术前后 pHPT 患者的 BDI-II 评分进行评估的研究均被纳入:文献检索共检索到 1554 项研究,其中 9 篇符合纳入标准。与对照组患者相比,pHPT患者的基线BDI-II评分明显较高。术后≤1个月和6个月时,pHPT患者的BDI-II评分出现了统计学意义上的显著下降:根据这项研究的结果,BDI-II评分≥14分的pHPT患者可能需要进行甲状旁腺切除术。
{"title":"Beck Depression Inventory-II Response Following Parathyroidectomy for Primary Hyperparathyroidism: A Systematic Review and Meta-Analyses.","authors":"Om S Chitnis, Sabrina K Wagner, J Joseph Caraway, Nora L Watson, Rhonda J Allard, Michael I Orestes","doi":"10.1002/hed.28003","DOIUrl":"https://doi.org/10.1002/hed.28003","url":null,"abstract":"<p><strong>Background: </strong>There is currently a lack of consensus regarding neuropsychiatric symptoms as an indication for parathyroidectomy in primary hyperparathyroidism (pHPT). The purpose of this study is to perform a systematic review and meta-analyses of pre- and postoperative Beck Depression Inventory-II (BDI-II) scores in patients with pHPT undergoing parathyroidectomy.</p><p><strong>Methods: </strong>A search of the literature was performed using Embase, PubMed, Web of Science, PsycINFO, and OvidAll EBM Reviews. Studies were included if they evaluated BDI-II scores in pHPT patients before and after parathyroidectomy.</p><p><strong>Results: </strong>The literature search returned 1554 studies, of which nine articles met criteria for inclusion. Baseline BDI-II scores were significantly higher in pHPT patients compared to control patients. pHPT patients experienced a statistically significant decrease in BDI-II scores at ≤ 1 and 6 months postoperatively.</p><p><strong>Conclusions: </strong>Based on the results of this study, a BDI-II score ≥ 14 could potentially advocate for parathyroidectomy in patients with pHPT.</p>","PeriodicalId":55072,"journal":{"name":"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142734773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
HPV-Associated Head and Neck Second Primary Tumors—A Case Series HPV相关头颈部第二原发肿瘤--病例系列。
IF 2.3 3区 医学 Q1 OTORHINOLARYNGOLOGY Pub Date : 2024-11-27 DOI: 10.1002/hed.28018
Shimrit Sharav, Joshua D. Horton, Zachary Theodossiou, John Turner, David Neskey, Terry Day

Background

There is limited understanding of head and neck second primary tumors (SPTs) in HPV-associated squamous cell carcinoma (SCC). Analogous to the concept of field cancerization of the upper airway known to contribute to the development of smoking-related head and neck SPTs, this case series reports four cases of HPV-associated SPTs.

Methods

We reviewed the charts of four patients diagnosed with HPV-associated oropharyngeal SCC who subsequently developed HPV-associated SPTs. Clinical data was collected, including demographics, tumor characteristics, time elapsed between the two diagnoses, and treatment type.

Results

The average age of the patients was 68 years. All of the patients were non-smokers, and none reported heavy alcohol use. All patients had the first cancer in the oropharynx. The time between the first and second diagnoses ranged from 3 and 12 years.

Conclusion

HPV has not been previously identified as a risk factor for head and neck SPTs. Given the long period between the first and second cancers and the lack of other risk factors for head and neck cancer, our case series demonstrates HPV-associated head and neck SPTs.

背景:人们对HPV相关鳞状细胞癌(SCC)的头颈部第二原发肿瘤(SPT)了解有限。已知上呼吸道野癌化是导致与吸烟相关的头颈部第二原发肿瘤(SPT)发生的原因,与此概念类似,本病例系列报告了四例与 HPV 相关的第二原发肿瘤:我们查阅了四例被诊断为HPV相关口咽SCC患者的病历,这些患者随后发展为HPV相关SPTs。我们收集了临床数据,包括人口统计学、肿瘤特征、两次诊断之间的时间间隔以及治疗类型:结果:患者的平均年龄为 68 岁。所有患者均不吸烟,无一人酗酒。所有患者的首次癌症都发生在口咽部。首次诊断与第二次诊断之间的时间间隔为 3 年至 12 年不等:结论:HPV 之前尚未被确定为头颈部 SPT 的风险因素。鉴于第一次和第二次癌症之间的间隔时间较长,且缺乏头颈部癌症的其他风险因素,我们的病例系列显示了与人乳头瘤病毒相关的头颈部 SPT。
{"title":"HPV-Associated Head and Neck Second Primary Tumors—A Case Series","authors":"Shimrit Sharav,&nbsp;Joshua D. Horton,&nbsp;Zachary Theodossiou,&nbsp;John Turner,&nbsp;David Neskey,&nbsp;Terry Day","doi":"10.1002/hed.28018","DOIUrl":"10.1002/hed.28018","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>There is limited understanding of head and neck second primary tumors (SPTs) in HPV-associated squamous cell carcinoma (SCC). Analogous to the concept of field cancerization of the upper airway known to contribute to the development of smoking-related head and neck SPTs, this case series reports four cases of HPV-associated SPTs.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We reviewed the charts of four patients diagnosed with HPV-associated oropharyngeal SCC who subsequently developed HPV-associated SPTs. Clinical data was collected, including demographics, tumor characteristics, time elapsed between the two diagnoses, and treatment type.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The average age of the patients was 68 years. All of the patients were non-smokers, and none reported heavy alcohol use. All patients had the first cancer in the oropharynx. The time between the first and second diagnoses ranged from 3 and 12 years.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>HPV has not been previously identified as a risk factor for head and neck SPTs. Given the long period between the first and second cancers and the lack of other risk factors for head and neck cancer, our case series demonstrates HPV-associated head and neck SPTs.</p>\u0000 </section>\u0000 </div>","PeriodicalId":55072,"journal":{"name":"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck","volume":"47 3","pages":"E32-E35"},"PeriodicalIF":2.3,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142734775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Low Skeletal Muscle Mass: A Strong Predictive Factor for Surgical Complications After Free Forearm Flap Reconstruction in Oral Cancer Patients. 骨骼肌质量低:口腔癌患者游离前臂皮瓣重建术后手术并发症的强预测因素
IF 2.3 3区 医学 Q1 OTORHINOLARYNGOLOGY Pub Date : 2024-11-27 DOI: 10.1002/hed.28014
E Ansari, N Carrillo Minulina, M A van Beers, R J J van Es, F J Dieleman, A J W P Rosenberg, L M Janssen, W W Braunius, E M Van Cann, R de Bree

Background: Low skeletal muscle mass (SMM) is a predictive factor for complications in patients undergoing major head and neck cancer surgery. This study aims to identify the predictive value of low SMM for postoperative complications in patients who underwent free forearm flap (FAFF) reconstructions after oral cancer resections.

Methods: A retrospective study was performed with all patients who underwent FFAF between 2003 and 2020 for an oral cavity reconstruction after cancer ablation. Free flap related, any postoperative complications and hospital stay were investigated.

Results: Low SMM was associated with an increased risk of free flap associated complications (OR 2.14; 95% CI 1.02-4.39, p = 0.029). Low SMM was associated with severe complications (Clavien-Dindo ≥ III) (OR 1.46; 95% CI 1.20-2.09, p = 0.02).

Conclusions: Low SMM is a strong predictive factor for free flap related surgical complications in patients undergoing FAFF reconstruction after resection of oral cancer.

背景:低骨骼肌质量(SMM)是头颈部癌症大手术患者出现并发症的一个预测因素。本研究旨在确定低骨骼肌质量对口腔癌切除术后接受游离前臂皮瓣(FAFF)重建患者术后并发症的预测价值:对 2003 年至 2020 年期间所有接受游离前臂皮瓣(FAFF)手术的癌症消融术后口腔重建患者进行回顾性研究。研究调查了游离皮瓣相关情况、术后并发症和住院时间:低 SMM 与游离皮瓣相关并发症的风险增加有关(OR 2.14;95% CI 1.02-4.39,P = 0.029)。低 SMM 与严重并发症(Clavien-Dindo ≥ III)相关(OR 1.46; 95% CI 1.20-2.09, p = 0.02):低SMM是口腔癌切除术后接受FAFF重建的患者出现游离皮瓣相关手术并发症的一个强有力的预测因素。
{"title":"Low Skeletal Muscle Mass: A Strong Predictive Factor for Surgical Complications After Free Forearm Flap Reconstruction in Oral Cancer Patients.","authors":"E Ansari, N Carrillo Minulina, M A van Beers, R J J van Es, F J Dieleman, A J W P Rosenberg, L M Janssen, W W Braunius, E M Van Cann, R de Bree","doi":"10.1002/hed.28014","DOIUrl":"https://doi.org/10.1002/hed.28014","url":null,"abstract":"<p><strong>Background: </strong>Low skeletal muscle mass (SMM) is a predictive factor for complications in patients undergoing major head and neck cancer surgery. This study aims to identify the predictive value of low SMM for postoperative complications in patients who underwent free forearm flap (FAFF) reconstructions after oral cancer resections.</p><p><strong>Methods: </strong>A retrospective study was performed with all patients who underwent FFAF between 2003 and 2020 for an oral cavity reconstruction after cancer ablation. Free flap related, any postoperative complications and hospital stay were investigated.</p><p><strong>Results: </strong>Low SMM was associated with an increased risk of free flap associated complications (OR 2.14; 95% CI 1.02-4.39, p = 0.029). Low SMM was associated with severe complications (Clavien-Dindo ≥ III) (OR 1.46; 95% CI 1.20-2.09, p = 0.02).</p><p><strong>Conclusions: </strong>Low SMM is a strong predictive factor for free flap related surgical complications in patients undergoing FAFF reconstruction after resection of oral cancer.</p>","PeriodicalId":55072,"journal":{"name":"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142734776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
LncRNA SNHG14 Facilitates Cisplatin Resistance Through Upregulating Notch2 via Binding to U2AF2 in Nasopharyngeal Carcinoma. LncRNA SNHG14在鼻咽癌中通过与U2AF2结合上调Notch2促进顺铂抗性
IF 2.3 3区 医学 Q1 OTORHINOLARYNGOLOGY Pub Date : 2024-11-27 DOI: 10.1002/hed.28016
Sijia Yan, Puhua Zhang, Shuai Tan, Haiyun Mo, Yanlin Yang

Background: Cisplatin (DDP) is one of the commonly used chemotherapeutic drugs for nasopharyngeal carcinoma (NPC) patients, and the resistance of tumor cells to cisplatin is main obstacle for NPC treatment. This study explored effect and possible mechanism of lncRNA small nucleolar RNA host gene 14 (SNHG14) on drug resistance of NPC cells to cisplatin.

Methods: Levels of SNHG14 and Notch2 in NPC tissues and cells were confirmed using RT-qPCR. Western blot detected Notch2 and ABCB1 expression in NPC cells. IC50 of cisplatin-treated NPC cells was tested utilizing 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT). Cell proliferation and apoptosis were evaluated utilizing colony formation experiment and flow cytometry, respectively. RNA immunoprecipitation (RIP) assay was utilized to validate the target genes of U2AF2. Notch2 mRNA stability was tested using actinomycin D.

Results: SNHG14 level was increased in both cisplatin-resistant NPC tissues and cell lines. SNHG14 silencing in HNE1/DDP cells resulted in inhibition of chemoresistance to cisplatin. Conversely, upregulation of SNHG14 in HNE1 cells enhanced their resistance to cisplatin. SNHG14 exhibited an interaction with U2AF2, leading to stabilization of Notch2 mRNA. Finally, Notch2 was involved in SNHG14-mediated cisplatin resistance in NPC cells.

Conclusion: Our findings demonstrate SNHG14 plays a significant role in promoting chemoresistance of NPC cells to cisplatin through U2AF2/Notch2 axis. These results highlight potential therapeutic targets for NPC treatment.

背景:顺铂(DDP)是鼻咽癌患者常用的化疗药物之一:顺铂(DDP)是鼻咽癌(NPC)患者常用的化疗药物之一,而肿瘤细胞对顺铂的耐药性是鼻咽癌治疗的主要障碍。本研究探讨了lncRNA小核RNA宿主基因14(SNHG14)对鼻咽癌细胞顺铂耐药性的影响及可能机制:方法:采用RT-qPCR技术确认SNHG14和Notch2在鼻咽癌组织和细胞中的水平。Western印迹检测了NPC细胞中Notch2和ABCB1的表达。利用 3-(4,5-二甲基噻唑-2-基)-2,5-二苯基溴化四氮唑(MTT)检测顺铂处理的鼻咽癌细胞的 IC50。细胞增殖和凋亡分别通过集落形成实验和流式细胞术进行评估。利用 RNA 免疫沉淀(RIP)试验验证了 U2AF2 的靶基因。使用放线菌素 D 检测 Notch2 mRNA 的稳定性:结果:SNHG14水平在顺铂耐药的鼻咽癌组织和细胞系中均有升高。在 HNE1/DDP 细胞中沉默 SNHG14 可抑制对顺铂的化疗耐药性。相反,HNE1细胞中SNHG14的上调增强了它们对顺铂的耐药性。SNHG14与U2AF2相互作用,导致Notch2 mRNA的稳定。最后,Notch2参与了SNHG14介导的NPC细胞对顺铂的耐药性:我们的研究结果表明,SNHG14在通过U2AF2/Notch2轴促进鼻咽癌细胞对顺铂的化疗耐药性方面发挥着重要作用。这些结果突显了治疗鼻咽癌的潜在靶点。
{"title":"LncRNA SNHG14 Facilitates Cisplatin Resistance Through Upregulating Notch2 via Binding to U2AF2 in Nasopharyngeal Carcinoma.","authors":"Sijia Yan, Puhua Zhang, Shuai Tan, Haiyun Mo, Yanlin Yang","doi":"10.1002/hed.28016","DOIUrl":"https://doi.org/10.1002/hed.28016","url":null,"abstract":"<p><strong>Background: </strong>Cisplatin (DDP) is one of the commonly used chemotherapeutic drugs for nasopharyngeal carcinoma (NPC) patients, and the resistance of tumor cells to cisplatin is main obstacle for NPC treatment. This study explored effect and possible mechanism of lncRNA small nucleolar RNA host gene 14 (SNHG14) on drug resistance of NPC cells to cisplatin.</p><p><strong>Methods: </strong>Levels of SNHG14 and Notch2 in NPC tissues and cells were confirmed using RT-qPCR. Western blot detected Notch2 and ABCB1 expression in NPC cells. IC50 of cisplatin-treated NPC cells was tested utilizing 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT). Cell proliferation and apoptosis were evaluated utilizing colony formation experiment and flow cytometry, respectively. RNA immunoprecipitation (RIP) assay was utilized to validate the target genes of U2AF2. Notch2 mRNA stability was tested using actinomycin D.</p><p><strong>Results: </strong>SNHG14 level was increased in both cisplatin-resistant NPC tissues and cell lines. SNHG14 silencing in HNE1/DDP cells resulted in inhibition of chemoresistance to cisplatin. Conversely, upregulation of SNHG14 in HNE1 cells enhanced their resistance to cisplatin. SNHG14 exhibited an interaction with U2AF2, leading to stabilization of Notch2 mRNA. Finally, Notch2 was involved in SNHG14-mediated cisplatin resistance in NPC cells.</p><p><strong>Conclusion: </strong>Our findings demonstrate SNHG14 plays a significant role in promoting chemoresistance of NPC cells to cisplatin through U2AF2/Notch2 axis. These results highlight potential therapeutic targets for NPC treatment.</p>","PeriodicalId":55072,"journal":{"name":"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142741500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Artificial Dermis Graft Following Basal Cell Carcinoma Removal on the Nose: A Comparison of Scar Contracture Across Nasal Subunits. 鼻基底细胞癌切除术后的人工真皮移植:鼻腔各亚单位瘢痕挛缩的比较。
IF 2.3 3区 医学 Q1 OTORHINOLARYNGOLOGY Pub Date : 2024-11-25 DOI: 10.1002/hed.28017
Kyu-Il Lee, Ye-Won Choi, Seung-Kyu Han, Seong-Ho Jeong, Eun-Sang Dhong

Background: This study aimed to compare the degree of scar contracture following artificial dermis grafting after excision of basal cell carcinoma on the nose categorized by defect location into three nasal subunits.

Methods: Anthropometric analysis was conducted on seven parameters using patients' photographs to compare changes between preoperative and postoperative measurements based on nasal subunits. Defect locations were classified as: (1) dorsum and sidewalls (D zone), (2) tip (T zone), and (3) alar lobule (A zone).

Results: The greatest change in alar height asymmetry was observed in zone A. Changes in nasal tip projection ratio and nasofrontal angle were the most significant in zone T. No other measurements showed statistically significant differences among the three zones.

Conclusions: Careful consideration is recommended when applying artificial dermis grafting in zones A and T. Conversely, zone D appears to be the most suitable for artificial dermis grafting.

背景:本研究旨在比较鼻部基底细胞癌切除术后人工真皮移植的瘢痕挛缩程度:本研究旨在比较鼻部基底细胞癌切除术后人工真皮移植后瘢痕挛缩的程度:方法:使用患者照片对七项参数进行人体测量分析,根据鼻腔亚单位比较术前和术后测量值的变化。缺陷位置分为(结果:鼻尖投影比和鼻额角的变化在 T 区最为显著:结论:在 A 区和 T 区进行人工真皮移植时应慎重考虑。
{"title":"Artificial Dermis Graft Following Basal Cell Carcinoma Removal on the Nose: A Comparison of Scar Contracture Across Nasal Subunits.","authors":"Kyu-Il Lee, Ye-Won Choi, Seung-Kyu Han, Seong-Ho Jeong, Eun-Sang Dhong","doi":"10.1002/hed.28017","DOIUrl":"https://doi.org/10.1002/hed.28017","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to compare the degree of scar contracture following artificial dermis grafting after excision of basal cell carcinoma on the nose categorized by defect location into three nasal subunits.</p><p><strong>Methods: </strong>Anthropometric analysis was conducted on seven parameters using patients' photographs to compare changes between preoperative and postoperative measurements based on nasal subunits. Defect locations were classified as: (1) dorsum and sidewalls (D zone), (2) tip (T zone), and (3) alar lobule (A zone).</p><p><strong>Results: </strong>The greatest change in alar height asymmetry was observed in zone A. Changes in nasal tip projection ratio and nasofrontal angle were the most significant in zone T. No other measurements showed statistically significant differences among the three zones.</p><p><strong>Conclusions: </strong>Careful consideration is recommended when applying artificial dermis grafting in zones A and T. Conversely, zone D appears to be the most suitable for artificial dermis grafting.</p>","PeriodicalId":55072,"journal":{"name":"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2024-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142717957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Predictors of Gastrostomy Tube Placement in Head and Neck Cancer Patients Undergoing Radiation or Chemoradiotherapy: A Systematic Review 接受放疗或化疗的头颈部癌症患者放置胃管的预测因素:系统回顾
IF 2.3 3区 医学 Q1 OTORHINOLARYNGOLOGY Pub Date : 2024-11-25 DOI: 10.1002/hed.28010
Jenny B. Xiao, Abhiram Cherukupalli, Khanh Linh Tran, Eitan Prisman

Background

Malnutrition is a major problem in head and neck cancer (HNC) with up to half of patients requiring gastrostomy tube (G-tube) placement. Predicting this need remains complex given mixed evidence surrounding its usage.

Methods

A comprehensive search was performed to identify studies examining risk factors associated with G-tube placement following radiotherapy (RT) or concurrent chemoradiotherapy (CCRT) in HNC patients.

Results

Sixteen retrospective studies were included (n = 11 015). The overall prevalence of G-tube placement was 44% with 76% of patients receiving reactive G-tube placement. Pretreatment dysphagia, pretreatment BMI < 18.5, and tumors in the hypopharynx were significant predictive factors for prophylactic G-tube placement. Type of chemotherapy regimen, tumors in the nasopharynx, and cytokine changes were significant predictive factors for reactive G-tube placement.

Conclusion

Several factors were identified that contribute to increased risk of G-tube placement and may guide current decision-making algorithms.

背景:营养不良是头颈癌(HNC)的一个主要问题,多达一半的患者需要放置胃造瘘管(G 管)。由于有关胃管使用的证据不一,因此预测这种需求仍然很复杂:方法:我们进行了一次全面检索,以确定与HNC患者放疗(RT)或同期化放疗(CCRT)后放置胃管相关的风险因素的研究:结果:共纳入16项回顾性研究(n = 11 015)。总的 G 管置入率为 44%,76% 的患者接受反应性 G 管置入。治疗前吞咽困难、治疗前体重指数 结论:研究发现了导致 G 管置入风险增加的几个因素,可为当前的决策算法提供指导。
{"title":"Predictors of Gastrostomy Tube Placement in Head and Neck Cancer Patients Undergoing Radiation or Chemoradiotherapy: A Systematic Review","authors":"Jenny B. Xiao,&nbsp;Abhiram Cherukupalli,&nbsp;Khanh Linh Tran,&nbsp;Eitan Prisman","doi":"10.1002/hed.28010","DOIUrl":"10.1002/hed.28010","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Malnutrition is a major problem in head and neck cancer (HNC) with up to half of patients requiring gastrostomy tube (G-tube) placement. Predicting this need remains complex given mixed evidence surrounding its usage.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A comprehensive search was performed to identify studies examining risk factors associated with G-tube placement following radiotherapy (RT) or concurrent chemoradiotherapy (CCRT) in HNC patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Sixteen retrospective studies were included (<i>n</i> = 11 015). The overall prevalence of G-tube placement was 44% with 76% of patients receiving reactive G-tube placement. Pretreatment dysphagia, pretreatment BMI &lt; 18.5, and tumors in the hypopharynx were significant predictive factors for prophylactic G-tube placement. Type of chemotherapy regimen, tumors in the nasopharynx, and cytokine changes were significant predictive factors for reactive G-tube placement.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Several factors were identified that contribute to increased risk of G-tube placement and may guide current decision-making algorithms.</p>\u0000 </section>\u0000 </div>","PeriodicalId":55072,"journal":{"name":"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck","volume":"47 3","pages":"1006-1017"},"PeriodicalIF":2.3,"publicationDate":"2024-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hed.28010","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142717960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Impact of Preoperative Facial Nerve Weakness and Facial Nerve Outcomes in the Management of Patients With Parotid Metastases of Cutaneous Squamous Cell Carcinoma. 皮肤鳞状细胞癌腮腺转移患者术前面部神经虚弱对面部神经治疗效果的影响
IF 2.3 3区 医学 Q1 OTORHINOLARYNGOLOGY Pub Date : 2024-11-25 DOI: 10.1002/hed.28005
Vivian Lin, Michael Zhang, Ruta Gupta, Michael S Elliott, Jonathan R Clark, James J Wykes, Sydney Ch'ng, Kerwin F Shannon, Carsten E Palme, Tsu-Hui Low

Background: Cutaneous squamous cell carcinomas (cSCC) metastasizing to the parotid gland can cause facial nerve (FN) dysfunction secondary to direct invasion, perineural spread, or surgical ablation. This study aims to characterize the prevalence of preoperative FN involvement in metastatic cSCC to the parotid and identify risk factors resulting in FN sacrifice.

Methods: Patients with parotid metastases from cSCC, treated surgically with parotidectomy with curative intent were identified through a retrospective cohort analysis of a prospectively maintained Sydney Head and Neck database from 1992 to 2021.

Results: Of 408 patients identified, 39 (10%) were found to have preoperative FN weakness, of which 41% underwent concurrent temporal bone resection compared to 9.1% for the overall cohort. All patients with preoperative FN weakness underwent FN sacrifice. FN sacrifice occurred in n = 145 (36%), of which 88 (61%) required sacrifice of a trunk or division. The 5-year disease free survival and disease specific survival was worse for patients requiring sacrifice of the FN trunk compared to no sacrifice, however there was no difference in survival for patients requiring sacrifice of the FN division or branch. We found those with > 23.5 mm parotid deposits had an odds ratio of 9.9 for FN sacrifice (95% CI 3.0-32.8, p < 0.001).

Conclusions: Preoperative FN weakness was present in 10% of patients and 36% had some part of the FN sacrificed. There was no significant difference in outcomes for patients with and without preoperative FN weakness. Patients who undergo sacrifice of the FN trunk have worse survival compared to those not requiring FN sacrifice, however similar outcomes were observed in those requiring lessor degrees of FN sacrifice. The likelihood FN sacrifice rises with increasing parotid deposit size.

背景:转移至腮腺的皮肤鳞状细胞癌(cSCC)可因直接侵犯、神经周围扩散或手术消融而导致面神经(FN)功能障碍。本研究旨在描述腮腺转移性 cSCC 术前 FN 受累的发生率,并确定导致 FN 牺牲的风险因素:通过对1992年至2021年期间悉尼头颈部前瞻性数据库的回顾性队列分析,确定了接受腮腺切除术治疗的腮腺转移cSCC患者:在确定的 408 例患者中,有 39 例(10%)发现术前 FN 薄弱,其中 41% 的患者同时接受了颞骨切除术,而整个队列中只有 9.1%的患者接受了颞骨切除术。所有术前 FN 薄弱的患者都接受了 FN 切除术。145例(36%)患者进行了FN切除,其中88例(61%)需要切除主干或分部。与不牺牲 FN 相比,需要牺牲 FN 主干的患者的 5 年无病生存率和疾病特异性生存率更低,但需要牺牲 FN 分部或分支的患者的生存率没有差异。我们发现,腮腺沉积物大于 23.5 毫米的患者牺牲 FN 的几率比为 9.9(95% CI 3.0-32.8,P,结论):10%的患者术前存在FN薄弱现象,36%的患者牺牲了部分FN。术前 FN 薄弱和术后 FN 薄弱的患者在治疗效果上没有明显差异。与不需要舍弃 FN 的患者相比,舍弃 FN 主干的患者生存率较低,但需要舍弃 FN 的程度较低的患者的预后也相似。随着腮腺沉积物体积的增大,牺牲 FN 的可能性也随之增大。
{"title":"The Impact of Preoperative Facial Nerve Weakness and Facial Nerve Outcomes in the Management of Patients With Parotid Metastases of Cutaneous Squamous Cell Carcinoma.","authors":"Vivian Lin, Michael Zhang, Ruta Gupta, Michael S Elliott, Jonathan R Clark, James J Wykes, Sydney Ch'ng, Kerwin F Shannon, Carsten E Palme, Tsu-Hui Low","doi":"10.1002/hed.28005","DOIUrl":"https://doi.org/10.1002/hed.28005","url":null,"abstract":"<p><strong>Background: </strong>Cutaneous squamous cell carcinomas (cSCC) metastasizing to the parotid gland can cause facial nerve (FN) dysfunction secondary to direct invasion, perineural spread, or surgical ablation. This study aims to characterize the prevalence of preoperative FN involvement in metastatic cSCC to the parotid and identify risk factors resulting in FN sacrifice.</p><p><strong>Methods: </strong>Patients with parotid metastases from cSCC, treated surgically with parotidectomy with curative intent were identified through a retrospective cohort analysis of a prospectively maintained Sydney Head and Neck database from 1992 to 2021.</p><p><strong>Results: </strong>Of 408 patients identified, 39 (10%) were found to have preoperative FN weakness, of which 41% underwent concurrent temporal bone resection compared to 9.1% for the overall cohort. All patients with preoperative FN weakness underwent FN sacrifice. FN sacrifice occurred in n = 145 (36%), of which 88 (61%) required sacrifice of a trunk or division. The 5-year disease free survival and disease specific survival was worse for patients requiring sacrifice of the FN trunk compared to no sacrifice, however there was no difference in survival for patients requiring sacrifice of the FN division or branch. We found those with > 23.5 mm parotid deposits had an odds ratio of 9.9 for FN sacrifice (95% CI 3.0-32.8, p < 0.001).</p><p><strong>Conclusions: </strong>Preoperative FN weakness was present in 10% of patients and 36% had some part of the FN sacrificed. There was no significant difference in outcomes for patients with and without preoperative FN weakness. Patients who undergo sacrifice of the FN trunk have worse survival compared to those not requiring FN sacrifice, however similar outcomes were observed in those requiring lessor degrees of FN sacrifice. The likelihood FN sacrifice rises with increasing parotid deposit size.</p>","PeriodicalId":55072,"journal":{"name":"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2024-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142711572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical Management Update of Oral Leukoplakia: A Review From the American Head and Neck Society Cancer Prevention Service 口腔白斑病的临床管理更新:美国头颈部协会癌症预防服务回顾。
IF 2.3 3区 医学 Q1 OTORHINOLARYNGOLOGY Pub Date : 2024-11-25 DOI: 10.1002/hed.28013
James C. Gates, Marianne Abouyared, Yelizaveta Shnayder, D. Gregory Farwell, Andrew Day, Faizan Alawi, Michael Moore, Andrew J. Holcomb, Andrew Birkeland, Joel Epstein

Background

Oral potentially malignant disorders (OPMDs) occur in up to 4%–5% of the population, of which oral leukoplakia (OL) is the most common subtype. Predicting high-risk OL remains a challenge. Early diagnosis and effective treatment are thought to be of paramount importance to improve outcomes.

Methods

We searched PubMed and Clinicaltrials.gov data for updates in the clinical management of OL from 2015 to current.

Results

Recent publication of large cohorts of patients with OL aids in counseling patients regarding risk of malignant transformation. Management for OL includes surveillance, excision, and laser surgery, as well as local and systemic approaches to chemoprevention. Several new entities show promise regarding candidate biomarkers, chemoprevention agents, and diagnostic adjuncts, though all require further validation.

Conclusion

This update serves to further inform clinical management of OL and provide impetus for future investigations.

Trial Registration

NCT00099021, NCT00951379, NCT05727761, NCT05727761

背景:口腔潜在恶性疾病(OPMDs)的发病率高达 4%-5%,其中口腔白斑病(OL)是最常见的亚型。预测高风险口腔白斑病仍是一项挑战。早期诊断和有效治疗对改善预后至关重要:我们搜索了 PubMed 和 Clinicaltrials.gov 数据,以了解 2015 年至今 OL 临床治疗的最新进展:最近发表的大型OL患者队列有助于为患者提供有关恶性转化风险的咨询。OL的治疗包括监测、切除和激光手术,以及局部和全身的化学预防方法。一些新的实体显示出候选生物标志物、化学预防药物和诊断辅助手段的前景,但所有这些都需要进一步验证:结论:这一更新有助于进一步为 OL 的临床管理提供信息,并为未来的研究提供动力:NCT00099021、NCT00951379、NCT05727761、NCT05727761。
{"title":"Clinical Management Update of Oral Leukoplakia: A Review From the American Head and Neck Society Cancer Prevention Service","authors":"James C. Gates,&nbsp;Marianne Abouyared,&nbsp;Yelizaveta Shnayder,&nbsp;D. Gregory Farwell,&nbsp;Andrew Day,&nbsp;Faizan Alawi,&nbsp;Michael Moore,&nbsp;Andrew J. Holcomb,&nbsp;Andrew Birkeland,&nbsp;Joel Epstein","doi":"10.1002/hed.28013","DOIUrl":"10.1002/hed.28013","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Oral potentially malignant disorders (OPMDs) occur in up to 4%–5% of the population, of which oral leukoplakia (OL) is the most common subtype. Predicting high-risk OL remains a challenge. Early diagnosis and effective treatment are thought to be of paramount importance to improve outcomes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We searched PubMed and Clinicaltrials.gov data for updates in the clinical management of OL from 2015 to current.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Recent publication of large cohorts of patients with OL aids in counseling patients regarding risk of malignant transformation. Management for OL includes surveillance, excision, and laser surgery, as well as local and systemic approaches to chemoprevention. Several new entities show promise regarding candidate biomarkers, chemoprevention agents, and diagnostic adjuncts, though all require further validation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This update serves to further inform clinical management of OL and provide impetus for future investigations.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Trial Registration</h3>\u0000 \u0000 <p>NCT00099021, NCT00951379, NCT05727761, NCT05727761</p>\u0000 </section>\u0000 </div>","PeriodicalId":55072,"journal":{"name":"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck","volume":"47 2","pages":"733-741"},"PeriodicalIF":2.3,"publicationDate":"2024-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11717973/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142711632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Head and Neck-Journal for the Sciences and Specialties of the Head and Neck
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1